Who is sponsoring NCT00556257?

NCT00556257 is sponsored by Pfizer.

What condition does NCT00556257 study?

NCT00556257 studies Kidney Transplantation.

What drugs are being tested in NCT00556257?

Interventions: Cyclosporine, CP-690-,550.

What is the status of NCT00556257?

NCT00556257 is currently WITHDRAWN.

Last reviewed 2008-05-27 · How we verify

A Pilot Randomized, Multicenter, Open-Label, Active Comparator-Controlled Trial Of A CP-690,550-Based Regimen In De Novo Kidney Allograft Recipients

NCT00556257 Phase 2 WITHDRAWN

A new immunosuppressive drug based on the inhibition of an important enzyme in the immune system called JAK3, is being developed by Pfizer to prevent transplant rejection. In this research study, a JAK3 inhibitor or cyclosporine will be given to new kidney transplant patients for 12 months in addition to other standard transplant medications such as prednisone.

Details

Lead sponsor	Pfizer
Phase	Phase 2
Status	WITHDRAWN
Start date	2007-08

Conditions

Kidney Transplantation

Interventions

Cyclosporine
CP-690-,550

Primary outcomes

Clinical biopsy proven acute rejection rate at 6 months — 6 months